FP-01.1

**FP-01.1** is an investigational synthetic universal influenza A vaccine developed by Immune Targeting Systems. It comprises six fluorocarbon-modified synthetic 35-mer peptides containing conserved CD4-positive and CD8-positive T-cell epitopes from influenza A internal proteins, including nucleoprotein, matrix protein 1, and polymerase basic proteins 1 and 2. The vaccine is designed to induce cross-reactive cellular immunity against divergent influenza A strains rather than primarily strain-specific neutralizing antibodies. It was administered intramuscularly in completed Phase 1 studies and a completed Phase 1/2 controlled human influenza-virus challenge study. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0264410X14007956))

Brand names

FlunisynFlunisyn™

Other names

Vaccine FP-01.1